Recent developments include reporting of Phase 2 clinical data for CAD-1005, completion of an $8.8 million private placement, and advancement of tecarfarin toward FDA rare pediatric disease filing.

• Cadrenal Therapeutics reported clinical data from its Phase 2 study of CAD-1005, noting fewer thrombotic events in the treatment group despite not meeting the primary endpoint [N2].
• The company announced an $8.8 million private placement to support operations and development activities [N3].
• Cadrenal advanced tecarfarin toward FDA rare pediatric disease filing in Kawasaki disease [N4].
• Recent analyst coverage includes buy and outperform recommendations from H.C. Wainwright and Noble Capital Markets [N8,N6].
• The company completed an End-of-Phase 2 meeting with the FDA clarifying a potential Phase 3 trial path for CAD-1005 in HIT patients [S1].

Cadrenal’s lead candidate CAD-1005 represents a novel mechanism targeting 12-LOX, potentially addressing an unmet need in HIT by interrupting immune-mediated platelet activation. The orphan drug and Fast Track designations may facilitate regulatory pathways and market access. Positive Phase 2 data showing reduced thrombotic events, despite not meeting the primary endpoint, supports further clinical development. The company’s pipeline diversification with tecarfarin and frunexian addresses additional cardiovascular and thrombotic indications with significant market potential. Strategic partnerships and out-licensing could provide non-dilutive funding and accelerate development. Manufacturing outsourcing allows operational flexibility without heavy capital investment.

Cadrenal faces significant financial challenges, including an accumulated deficit of approximately $44.8 million and cash resources insufficient to meet anticipated needs beyond twelve months, raising substantial doubt about its ability to continue as a going concern. The Phase 2 trial of CAD-1005 did not meet its primary endpoint, and the planned Phase 3 trial remains subject to FDA review and financing availability. The company lacks long-term manufacturing and commercialization agreements, relying on third parties, which may pose supply and regulatory risks. Competition from established anticoagulants is intense, and the company’s novel therapies face clinical and regulatory uncertainties. The pivot to a partnership model introduces execution risks, including the uncertainty of securing suitable collaborators or financing on acceptable terms.

Cadrenal Therapeutics’ moat is primarily based on its novel therapeutic approach with CAD-1005, a selective 12-LOX inhibitor addressing the underlying immune-mediated pathophysiology of heparin-induced thrombocytopenia (HIT), a condition with limited treatment options and high morbidity. CAD-1005’s orphan drug and Fast Track designations provide regulatory incentives and potential market exclusivity. The company’s pipeline includes tecarfarin, designed to overcome limitations of warfarin in complex patient populations, and frunexian, a unique intravenous Factor XIa inhibitor for acute care. Intellectual property rights acquired through asset purchases and exclusive licenses underpin proprietary technology. However, the company faces competition from established anticoagulants and must navigate clinical, regulatory, and financial risks. The reliance on third-party manufacturing and absence of commercialization partnerships may limit operational control and scalability.

• Liquidity and Going Concern Risk: The company has an accumulated deficit and expects to incur continued losses. Cash and cash equivalents are insufficient to meet anticipated cash requirements for the next twelve months, raising substantial doubt about its ability to continue as a going concern without additional financing [S2].
• Clinical Development Risk: CAD-1005 failed to meet the primary endpoint in its Phase 2 trial, and the Phase 3 pivotal trial protocol remains subject to FDA review and financing availability. Clinical trial outcomes and regulatory approvals are uncertain [S1].
• Financing and Dilution Risk: The company requires additional financing to advance clinical trials and operations. Financing efforts may involve equity issuance causing dilution, debt with restrictive covenants, or partnerships requiring relinquishment of rights [S2,S13,S14].
• Manufacturing and Supply Risk: Cadrenal relies on third-party CDMOs for manufacturing and has no long-term supply or commercialization agreements, exposing it to risks of supply disruptions, regulatory compliance issues, and loss of manufacturing partners [S5,S19].
• Competitive Risk: The company faces competition from established anticoagulants including warfarin, DOACs, and other parenteral agents. Market acceptance and differentiation of novel therapies are uncertain [S6].
• Regulatory and Market Risks: Regulatory approvals, market adoption, reimbursement, and compliance with complex laws and regulations pose ongoing risks. Changes in Nasdaq listing requirements and market conditions may affect stock liquidity and listing status [S2].

• Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing therapies for life-threatening immune and thrombotic conditions [S1].
• The company acquired a 12-lipoxygenase (12-LOX) platform in December 2025, shifting its primary focus to CAD-1005, a first-in-class selective 12-LOX inhibitor for treating heparin-induced thrombocytopenia (HIT) [S1].
• CAD-1005 has orphan drug designation (ODD) from the FDA for prophylaxis of thrombosis in HIT patients, FDA Fast Track designation for treatment and prevention of HIT, and an orphan designation from the EMA for platelet-activating factor 4 disorders [S1].
• CAD-1005 has undergone Phase 1 clinical trials in over 100 patients and a blinded, placebo-controlled Phase 2 trial with 24 patients [S1].
• The Phase 2 trial did not meet its primary endpoint (platelet count recovery rate) but showed fewer thrombotic events in the CAD-1005 group compared to placebo, though not statistically significant due to small sample size [S1].
• The company completed an End-of-Phase 2 meeting with the FDA on March 26, 2026, clarifying a potential registrational path for a planned Phase 3 pivotal trial of CAD-1005 in HIT patients; the Phase 3 protocol remains subject to FDA review and finalization [S1].
• Cadrenal's broader pipeline includes tecarfarin, an oral vitamin K antagonist designed as a warfarin replacement for patients with complex needs such as kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a Phase 2-ready intravenous Factor XIa inhibitor for acute care settings [S1].
• Tecarfarin has orphan drug and Fast Track designations from the FDA for prevention of systemic thromboembolism in patients with end stage kidney disease and atrial fibrillation, and for thrombosis prevention in patients with mechanical circulatory support devices including LVADs [S1].
• Tecarfarin has been evaluated in 11 clinical trials involving over 1,000 individuals, with favorable safety and tolerability profiles [S1].
• The company completed manufacturing of tecarfarin drug product under cGMP and has contracts with third-party pharmaceutical contract development and manufacturing organizations (CDMOs) for supply of active pharmaceutical ingredients and clinical trial material, but no long-term supply or commercialization agreements are in place [S1,S5].
• Cadrenal does not have its own manufacturing infrastructure and intends to rely on third-party CDMOs for production and distribution of product candidates [S5,S19].
• The company faces competition from existing anticoagulants including warfarin, direct oral anticoagulants (DOACs), and other parenteral anticoagulants; CAD-1005 is currently the only selective 12-LOX inhibitor in clinical development [S6].
• Cadrenal has an accumulated deficit of approximately $44.8 million as of June 30, 2026, and reported a net loss of approximately $5.8 million for the six months ended June 30, 2026 [S2].
• As of June 30, 2026, the company had cash and cash equivalents of approximately $2.39 million and current assets of about $5.58 million, with current liabilities of approximately $1.50 million, resulting in a current ratio of 3.73 and a cash ratio of 1.6 [S2].
• The company’s financial statements have been prepared assuming it will continue as a going concern, but there is substantial doubt about its ability to continue as such for one year after the financial statements are issued due to expected cash requirements exceeding current cash [S2].
• Management has pivoted to a partnership and out-licensing strategy to alleviate liquidity pressures, focusing on securing strategic out-licensing agreements, non-dilutive financing, and cost containment [S2,S13].
• The company completed an $8.8 million private placement announced July 1, 2026 [N3].
• Recent clinical data from the Phase 2 study of CAD-1005 was reported on July 13, 2026 [N2].
• The company advanced tecarfarin toward FDA rare pediatric disease filing in Kawasaki disease as of June 22, 2026 [N4].
• Cadrenal has received analyst coverage with buy and outperform recommendations from H.C. Wainwright and Noble Capital Markets [N8,N6].